Citadel Advisors
ABOS icon

Citadel Advisors’s Acumen Pharmaceuticals ABOS Stock Holding History

Citadel Advisors’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,000
Closed -$28.3K – 13579
2026
Q1 		$28.3K Buy
+12,000
New +$30.6K ﹤0.01% 12588
2025
Q2 		– Sell
-27,500
Closed -$30.3K – 12309
2025
Q1 		$30.3K Sell
27,500
-15,800
-36% -$22.6K ﹤0.01% 12817
2024
Q4 		$74.5K Sell
43,300
-6,200
-13% -$14.9K ﹤0.01% 11874
2024
Q3 		$123K Buy
49,500
+17,000
+52% +$46.1K ﹤0.01% 10841
2024
Q2 		$78.7K Buy
32,500
+22,900
+239% +$72.9K ﹤0.01% 11235
2024
Q1 		$38.9K Sell
9,600
-3,200
-25% -$12.1K ﹤0.01% 12420
2023
Q4 		$49.2K Sell
12,800
-2,400
-16% -$7.12K ﹤0.01% 11795
2023
Q3 		$63.1K Sell
15,200
-3,700
-20% -$22.9K ﹤0.01% 11460
2023
Q2 		$90.9K Buy
+18,900
New +$90.5K ﹤0.01% 11071
2023
Q1 		– Sell
-700
Closed -$3.78K – 14628
2022
Q4 		$3.78K Buy
+700
New +$4.7K ﹤0.01% 14171
2022
Q2 		– Sell
-20,000
Closed -$78K – 12756
2022
Q1 		$78K Buy
+20,000
New +$109K ﹤0.01% 12490

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Citadel Advisors's ABOS Position: Q2 2026 in Review

Citadel Advisors opened a new position in Acumen Pharmaceuticals (ABOS) in Q2 2026: 51,049 shares worth $136K. The stake represents ﹤0.01% of the portfolio and ranks #12428 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ABOS as recently as Q4 2025.

Citadel Advisors first reported a position in ABOS in Q3 2021 and has held it in 15 quarters since. The position peaked at $845K in Q3 2025. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Citadel Advisors held 51,049 shares of Acumen Pharmaceuticals worth $136K as of Q2 2026.
  • Acumen Pharmaceuticals was a new Citadel Advisors position in Q2 2026.
  • Acumen Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12428 holding.
  • Citadel Advisors first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 15 quarters since.
  • Citadel Advisors's Acumen Pharmaceuticals position peaked at $845K in Q3 2025.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.